The Revised International Prognostic Scoring System (IPSS-R) is a validated tool published in 2012 by Greenberg et al. that stratifies MDS patients into five risk groups (Very Low, Low, Intermediate, High, Very High) based on cytogenetics, bone marrow blasts, hemoglobin, platelets, and ANC.

How is the cytogenetic score determined?

Cytogenetics are grouped into five tiers: Very Good (−Y, del(11q)), Good (normal, del(5q), del(12p), del(20q), double including del(5q)), Intermediate (del(7q), +8, +19, i(17q), any other single or double clone), Poor (−7, inv(3)/t(3q)/del(3q), double including −7/del(7q), complex 3 abnormalities), and Very Poor (complex >3 abnormalities).

What are the five IPSS-R risk categories?

Scores ≤1.5 = Very Low (median OS ~8.8 years), >1.5–3 = Low (~5.3 years), >3–4.5 = Intermediate (~3 years), >4.5–6 = High (~1.6 years), >6 = Very High (~0.8 years). These are population medians and vary by individual factors.

Is this calculator a replacement for clinical judgment?

No. The IPSS-R is one prognostic input among many. Always interpret results in the full clinical context and consult a hematologist-oncologist for treatment planning.

What if bone marrow blasts are ≥20%?

A blast count ≥20% reclassifies the diagnosis from MDS to AML (acute myeloid leukemia) per WHO criteria. The IPSS-R applies to MDS (blasts <20%).

IPSS-R MDS Score

Name: IPSS-R MDS Score
Availability: InStock
Author: Nham Vu

Enter five clinical parameters to calculate the IPSS-R score, risk category, and estimated median overall survival for MDS patients.

Clinical Parameters

Cytogenetic Risk Group

Bone Marrow Blasts (%)

Must be <20% (values ≥20% indicate AML, not MDS)

Hemoglobin (g/dL)

Platelets (×10⁹/L)

ANC (×10⁹/L)

Enter clinical parameters and click Calculate

Results appear here

Summary

Enter five clinical parameters to calculate the IPSS-R score, risk category, and estimated median overall survival for MDS patients.

How it works

Each parameter is mapped to a subscale score using the published IPSS-R weighting table.
The five subscale scores are summed to produce the total IPSS-R score.
The total score is mapped to one of five risk categories with corresponding median overall survival estimates.

Use cases

Estimate prognosis for newly diagnosed MDS patients.
Guide treatment decisions — watch-and-wait vs. transplant evaluation.
Communicate risk category to patients and families.
Determine appropriate clinical trial eligibility criteria.
Track risk reclassification after re-biopsy.

Frequently Asked Questions

Last updated: 2026-07-23 · Reviewed by Nham Vu